LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

Home・Listă Acțiuni・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Deschisă

3.85 -2.53

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.83

Maxim

3.99

Indicatori cheie
By Trading Economics
Venit	-511K -28M
Vânzări	-13M 2.6M
EPS	-0.47
Marjă de profit	-1,077.401
Angajați	141
EBITDA	-455K -29M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+295.3% upside

Dividende
By Dow Jones
Următoarele câștiguri	4 aug. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-7.5M 227M
Deschiderea anterioară	6.38
Închiderea anterioară	3.85

Voyager Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 mai 2026, 21:33 UTC

Câștiguri

Correction to Salesforce 1Q Sales, Profit Rise Article

27 mai 2026, 21:00 UTC

Achiziții, Fuziuni, Preluări

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 mai 2026, 20:18 UTC

Câștiguri

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27 mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 mai 2026, 21:29 UTC

Acțiuni populare

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 mai 2026, 21:08 UTC

Câștiguri

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 mai 2026, 21:02 UTC

Câștiguri

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 mai 2026, 20:59 UTC

Achiziții, Fuziuni, Preluări

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 mai 2026, 20:55 UTC

Câștiguri

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 mai 2026, 20:48 UTC

Câștiguri

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 mai 2026, 20:45 UTC

Câștiguri

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 mai 2026, 20:34 UTC

Achiziții, Fuziuni, Preluări

Webster Financial Stockholders Approve Sale to Banco Santander

27 mai 2026, 20:32 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 mai 2026, 20:32 UTC

Achiziții, Fuziuni, Preluări

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 mai 2026, 20:32 UTC

Achiziții, Fuziuni, Preluări

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 mai 2026, 20:30 UTC

Câștiguri

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 mai 2026, 20:30 UTC

Achiziții, Fuziuni, Preluări

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 mai 2026, 20:22 UTC

Câștiguri

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mai 2026, 20:16 UTC

Câștiguri

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 mai 2026, 20:13 UTC

Câștiguri

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 mai 2026, 20:13 UTC

Câștiguri

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 mai 2026, 20:13 UTC

Câștiguri

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 mai 2026, 20:12 UTC

Câștiguri

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 mai 2026, 20:12 UTC

Câștiguri

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Comparație

Modificare preț

Voyager Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

295.3% sus

Prognoză pe 12 luni

Medie 15.14 USD 295.3%

Maxim 25 USD

Minim 8 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruVoyager Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Voyager Therapeutics Inc - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.